{"title":"用依托泊苷和顺铂成功治疗前列腺神经内分泌癌。","authors":"Masanori Ishizaki, Masaru Hasumi, Kazumichi Muramatsu, Nobuaki Shimizu","doi":"10.1002/iju5.12787","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>The frequency of neuroendocrine carcinoma of the prostate is low, accounting for approximately 1%–5% of all prostate cancers. Herein, we report the case of a patient who was diagnosed with prostate neuroendocrine carcinoma and successfully treated with etoposide and cisplatin.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>A 74-year-old man presented to the urology department with the chief complaint of urinary retention. After a thorough examination, he was diagnosed with neuroendocrine carcinoma of the prostate and treated with etoposide and cisplatin, called “EP therapy.” The patient remained in remission 1 year later.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>A patient with neuroendocrine carcinoma of the prostate was successfully treated with etoposide and cisplatin, and the patient remained in remission. Prostate neuroendocrine carcinomas are rare and have poor prognoses. Therefore, information regarding treatments that can improve prognosis is needed.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 6","pages":"491-494"},"PeriodicalIF":0.0000,"publicationDate":"2024-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531870/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prostate neuroendocrine carcinoma successfully treated with etoposide and cisplatin\",\"authors\":\"Masanori Ishizaki, Masaru Hasumi, Kazumichi Muramatsu, Nobuaki Shimizu\",\"doi\":\"10.1002/iju5.12787\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n <section>\\n \\n <h3> Introduction</h3>\\n \\n <p>The frequency of neuroendocrine carcinoma of the prostate is low, accounting for approximately 1%–5% of all prostate cancers. Herein, we report the case of a patient who was diagnosed with prostate neuroendocrine carcinoma and successfully treated with etoposide and cisplatin.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Case presentation</h3>\\n \\n <p>A 74-year-old man presented to the urology department with the chief complaint of urinary retention. After a thorough examination, he was diagnosed with neuroendocrine carcinoma of the prostate and treated with etoposide and cisplatin, called “EP therapy.” The patient remained in remission 1 year later.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>A patient with neuroendocrine carcinoma of the prostate was successfully treated with etoposide and cisplatin, and the patient remained in remission. Prostate neuroendocrine carcinomas are rare and have poor prognoses. Therefore, information regarding treatments that can improve prognosis is needed.</p>\\n </section>\\n </div>\",\"PeriodicalId\":52909,\"journal\":{\"name\":\"IJU Case Reports\",\"volume\":\"7 6\",\"pages\":\"491-494\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-09-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11531870/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"IJU Case Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12787\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
Prostate neuroendocrine carcinoma successfully treated with etoposide and cisplatin
Introduction
The frequency of neuroendocrine carcinoma of the prostate is low, accounting for approximately 1%–5% of all prostate cancers. Herein, we report the case of a patient who was diagnosed with prostate neuroendocrine carcinoma and successfully treated with etoposide and cisplatin.
Case presentation
A 74-year-old man presented to the urology department with the chief complaint of urinary retention. After a thorough examination, he was diagnosed with neuroendocrine carcinoma of the prostate and treated with etoposide and cisplatin, called “EP therapy.” The patient remained in remission 1 year later.
Conclusion
A patient with neuroendocrine carcinoma of the prostate was successfully treated with etoposide and cisplatin, and the patient remained in remission. Prostate neuroendocrine carcinomas are rare and have poor prognoses. Therefore, information regarding treatments that can improve prognosis is needed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
